Dr. Charles W. Drescher
Claim this profileProvidence Portland Medical Center
Studies Breast Cancer
Studies Non-Small Cell Lung Cancer
53 reported clinical trials
99 drugs studied
Area of expertise
1Breast Cancer
Stage IV
HER2 negative
Stage II
2Non-Small Cell Lung Cancer
Stage IV
MET positive
Stage II
Affiliated Hospitals
Clinical Trials Charles W. Drescher is currently running
Atezolizumab + Chemotherapy
for Neuroendocrine Carcinoma
This trial is testing a new treatment combining an immune-boosting drug with standard chemotherapy for patients with a specific type of aggressive cancer that has spread. The goal is to help the immune system fight the cancer and use chemotherapy to kill cancer cells.
Recruiting1 award Phase 2 & 310 criteria
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint High 2 Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
More about Charles W. Drescher
Clinical Trial Related8 years of experience running clinical trials · Led 53 trials as a Principal Investigator · 30 Active Clinical TrialsTreatments Charles W. Drescher has experience with
- Venetoclax
- Atezolizumab
- Pembrolizumab
- Nivolumab
- Cyclophosphamide
- Paclitaxel
Breakdown of trials Charles W. Drescher has run
Breast Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Charles W. Drescher specialize in?
Charles W. Drescher focuses on Breast Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Breast Cancer has involved Stage IV patients, or patients who are HER2 negative.
Is Charles W. Drescher currently recruiting for clinical trials?
Yes, Charles W. Drescher is currently recruiting for 30 clinical trials in Portland Oregon. If you're interested in participating, you should apply.
Are there any treatments that Charles W. Drescher has studied deeply?
Yes, Charles W. Drescher has studied treatments such as Venetoclax, Atezolizumab, Pembrolizumab.
What is the best way to schedule an appointment with Charles W. Drescher?
Apply for one of the trials that Charles W. Drescher is conducting.
What is the office address of Charles W. Drescher?
The office of Charles W. Drescher is located at: Providence Portland Medical Center, Portland, Oregon 97213 United States. This is the address for their practice at the Providence Portland Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.